Smith Martin Alexander, Executive Vice President, has demonstrated a consistent pattern of selling activity in shares of IDEXX Laboratories Inc. (IDXX) over the past several years, as evidenced by SEC Form 4 filings. Alexander has executed 25 transactions, all involving IDXX, with a total sell value of $420,093.85 and no recorded purchases. Notably, the most significant sales occurred on February 14, 2026, with a transaction valued at $190,063.70, and February 14, 2025, with a sale worth $166,254.22. Smaller transactions include $60,540.48 on February 14, 2024, and $3,235.45 on September 1, 2025. The majority of these transactions were classified as dispositions under Rule 16b-3, indicating they were likely part of planned sales or exercises of derivative securities.
Alexander’s trading activity is exclusively concentrated in IDXX, reflecting a long-term association with the company. The absence of any buy transactions suggests a focus on liquidating holdings rather than accumulating shares. While the transactions span multiple years, they are clustered around specific dates, particularly mid-February, which may align with scheduled vesting periods or other corporate events. The data does not indicate recent trading activity, as the most recent transaction occurred in February 2026. Overall, Alexander’s trading history reveals a clear bias toward selling IDXX shares, with no evidence of diversification into other securities.
AI-assisted summary